معرفی
Ziding Feng, PhD, is a Professor in the Biostatistics Program within the Public Health Sciences Division at Fred Hutchinson Cancer Center. He holds dual membership in the Pathogen-Associated Malignancies Integrated Research Center (PAM IRC) and the Translational Data Science Integrated Research Center (TDS IRC). As principal investigator for multiple National Cancer Institute (NCI) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiatives, including the Early Detection Research Network (EDRN) Data Management and Coordinating Center, he coordinates multicenter biomarker validation studies across prostate, liver, lung, colon, and esophageal cancers.
Dr. Feng's educational background includes:
- PhD in Biometry from Cornell University (1990)
- MS in Entomology from Cornell University (1985)
- BS in Plant Protection from Nanjing Agricultural University (1982)
His research centers on biomarker evaluation for cancer risk assessment and early detection, with pioneering work in statistical methodologies for phase III/IV clinical trials. He develops advanced analytical frameworks for longitudinal biomarker data and cancer screening efficacy assessment, particularly addressing challenges like overdiagnosis in hepatocellular carcinoma and pancreatic cancer detection. His expertise bridges biostatistics, translational oncology, and data science to optimize early cancer detection protocols.
Recent publications (2018-2024) reveal a strategic focus on methodological innovation for emerging cancer detection technologies. Key themes include Bayesian screening algorithms for liver cancer, statistical blueprints for biomarker validation, and rigorous clinical utility study designs. His work consistently addresses translational gaps between biomarker discovery and clinical implementation, with emphasis on pancreatic and liver cancer applications.
Professional recognition includes:
- Fellow, American Statistical Association (2007)
Dr. Feng directs over $20 million in active grants as PI for NCI-funded centers including the EDRN ($7.5M), Translational Liver Cancer Consortium, New Onset Diabetes Coordinating Center (NIDDK/NCI), and Pancreatic Cancer Early Detection Initiative (PanCAN). His leadership in the Cancer Screening Research Network (CSRN) Statistics and Data Management Center drives national screening trial infrastructure. These projects support 15+ concurrent clinical studies across four cancer types.
At Fred Hutch, he co-leads the Pathogen-Associated Malignancies IRC and Translational Data Science IRC, directing biostatistical teams for the EDRN's 30-institution network. His lab develops computational pipelines for multi-omics biomarker integration and real-world evidence analysis, currently supporting seven active clinical validation studies including the National Liver Cancer Screening Trial (Phase IV) and Cologuard impact assessment.
